SHR-1701 Combined with SHR2554 and BP102 for MCRC
NCT06679673 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2024-11-07
Summary
Response to oncologic treatment in mCRC is currently limited.
Conditions
- Colorectal Cancer Metastatic
Interventions
- DRUG
-
SHR-1701
SHR-1701
- DRUG
-
BP102
BP102
- DRUG
-
SHR2554
SHR2554
Sponsors & Collaborators
-
Fudan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-31
- Primary Completion
- 2025-12-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT07071714 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877 ·Status: COMPLETED
-
Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01679327 ·Status: UNKNOWN ·Phase: PHASE2
-
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
NCT03645876 ·Status: TERMINATED ·Phase: PHASE2
-
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
NCT06763029 ·Status: RECRUITING ·Phase: PHASE2
-
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
NCT03380689 ·Status: WITHDRAWN ·Phase: PHASE1
-
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01280643 ·Status: TERMINATED ·Phase: NA
-
Second-line Treatment of Metastatic Colorectal Cancer
NCT06242067 ·Status: RECRUITING ·Phase: PHASE2
-
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis
NCT06801665 ·Status: RECRUITING ·Phase: PHASE2
-
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
NCT06199973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
NCT06089330 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
NCT04230187 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
NCT04073615 ·Status: TERMINATED ·Phase: PHASE1
-
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT00467142 ·Status: COMPLETED ·Phase: PHASE2
-
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
NCT07134205 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01075048 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
NCT01900717 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
NCT06717880 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
NCT06195670 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
NCT02226289 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
NCT04627142 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
NCT05818267 ·Status: RECRUITING ·Phase: NA
-
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
NCT06060704 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
NCT06643793 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
NCT01453257 ·Status: COMPLETED ·Phase: PHASE2